摘要
目的:探讨替格瑞洛治疗动脉介入治疗(percutaneous coronary intervention,PCI)术后支架内血栓的疗效和安全性。方法:选择2013年1月—2015年1月收治的110例行PCI术后支架内血栓患者,按随机数字表法分为对照组和观察组各55例。对照组患者术后采取常规治疗,观察组患者给予替格瑞洛治疗,观察2组支架内血栓形成情况。结果:对照组患者急性支架内血栓、亚急性支架内血栓、晚期支架血栓、极晚期支架血栓形成率为21.82%、23.64%、14.55%、7.27%,观察组为7.27%、9.09%、3.64%、0.00%,观察组患者各种血栓形成率均明显低于对照组,差异有统计学意义(P<0.05);2组患者治疗过程中均无室性停搏、出血、呼吸困难等不良反应发生。结论:PCI术后支架内血栓患者采用替格瑞洛治疗,安全、可靠,效果显著,值得临床推广。
OBJECTIVE:To probe into the efficacy and safety of ticagrelor therapy in treatment of stent thrombosis after PCI.METHODS:110 cases with stent thrombosis after PCI admitted into the hospital from Jan.2013 to Jan.2015 were divided into the control group and observation group via the random number table,with 55 cases in each group.The control group received the conventional treatment after surgery,the observation group were treated with ticagrelor therapy,stent thrombosis of two groups were observed.RESULTS:The acute stent thrombosis,subacute stent thrombosis,late stent blood and extremely late stent thrombosis rate in control group were respectively 21.82%,23.64%,14.55% and 7.27%,while in observation group were respectively 7.27%,9.09%,3.64% and 0.00%;the thrombosis rates of observation group were significantly lower than that of the control group,with statistically significant difference( P〈0.05).There were no adverse reactions like ventricular arrest,bleeding and dyspnea during the treatment in two group of patients.CONCLUSIONS:The ticagrelor therapy in treatment of patients with stent thrombosis after PCI is safe and reliable,which has significant effect and is worthy of clinical promotion.
出处
《中国医院用药评价与分析》
2015年第11期1452-1454,共3页
Evaluation and Analysis of Drug-use in Hospitals of China